TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: overall subjective ocular symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehension of the information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adequate time to address concerns and answer questions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Atazanavir AUC0-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atazanavir Ctau
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of clinical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of gastroesophageal reflux disease (GERD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Paclitaxel-related neuropathy (grade 2 or greater)
Endpoint domain: Adverse events/effects
Primary endpoint: 3-month composite cardio-cerebral vascular event rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Markers of angiogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of PSA Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall procedure satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dimensional change of the alveolar crest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in QTcF interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aspartate transaminase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial Thromboplastin Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Total Improvement Score (TIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Extra-cellular volume (ECV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in patient pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma viral load < 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hours UFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in perceptions of the robot's cultural competency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Flares Per Participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy as determined by Total Numeric Transformed Modified Ashworth scale (TNmAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference in BOLD-fMRI intensity signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in BOLD-fMRI distribution signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite efficacy endpoint (death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, hemodynamic shock)
Endpoint domain: Mortality/survival
Primary endpoint: Major bleeding event (ISTH definition)
Endpoint domain: Adverse events/effects
Primary endpoint: Cut-off values of targeted DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Subjects With Reduction in Uterine Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Total Myoma Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embryos that were graded as a top quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of Infective Endocarditis (IE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of mutation in erythroid colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absolute Change From Baseline in Maximum Forced Expiratory Volume Within 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of successful abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Fluorescein and rose bengal staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentrations (Cmax) of JNJ-64251330
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Observed Plasma Concentration (Ctrough) of JNJ-64251330
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve from 0 to 24 Hour (AUC [0-24 h]) of JNJ-64251330
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epigenetic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satiety Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Amount of FFP transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximal and pain-free walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right colon adenoma miss rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Participants Achieving the modulatory effect on the GI tract flora composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of Lactobacillus helveticus populations in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cardiac Glucose Uptake During Normoxic Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glucose Uptake From Normoxia to Hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long term effectiveness of Oral Appliance therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Impact on cardiovascular morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Impact on cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: expected residual normal renal tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Outcomes of anorexia nervosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-gB titre level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability pension
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: pCR for Muscle Invasive Bladder Cancer (MIBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development of neointimal hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of anti-TB drug regimens
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and intensity of vasomotor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 30-Second Chair Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of XP21279
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamics of XP21279
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of XP21279
Endpoint domain: Adverse events/effects
Primary endpoint: Stage Improvement in Liver Fibrosis (METAVIR Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Frequency of MODY
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adverse events related to Sorafenib
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of repeat abortions
Endpoint domain: Mortality/survival
Primary endpoint: incidence of severe sepsis/septic shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall objective responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child anthropometry - height for age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child anthropometry - weight for age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child anthropometry - stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of standardized uptake values (SUVs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of visual axis opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of inflammatory deposits on Intraocular lens surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anterior-posterior synechia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurements of Intraocular lens tilt and decentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of online QFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immune-related Adverse Events (irAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With no Heavy Drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Days With Heavy Drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Days With Any Drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Conditional Odds Ratio of Patients Screened for Colorectal Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Conditional Odds Ratio of Patients Screened for Social Needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of surviving patients
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival Rate at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Body-weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melatonin concentration in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement of comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of carotid intima media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Buccal volume variation (BVv)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total volume variation (TVv)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Shoulder and Elbow Surgeon (ASES) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in National Institute of Health Stroke Scale (NIHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in modified Rankin Scale (mRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Barthel index (BI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Detectable CEM for SRC Foci
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in apoptosis in tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in proliferation of tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean time taken to achieve target hemoglobin (Hb) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Hb Concentration Between Baseline and EEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Maintaining Hb Concentration Within the Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in CD4+/CD8+ ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TH1/TH2 cytokine profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Conversion from anergic to reactive skin testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Size and classification of injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-alcoholic Fatty Liver Disease Ultrasonography Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Numerical Rating Scale (NRS) score of itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Passive range of motion of ankle dorsi-plantarflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy and precision of markers for measuring GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Penn State Worry Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of corticosteroids delivered to the nose vs. mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seborrhoea level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: acne severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PAHPI: post-acne hyperpigmentation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of gastric events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 'off'-time duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-removal of endotracheal tube
Endpoint domain: Adverse events/effects
Primary endpoint: self-removal of central venous or bladder catheters
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity to identify and visualize parathyroid adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Systolic Acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Professional burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mindfulness level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sustained ROSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Recanalization of the Chronic Total Occlusion (CTO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful Predilatation of the CTO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic yield (sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and tolerability of NW-3509A
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of volunteers with moderate or greater and/or vaccine related unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of volunteers with vaccine-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of volunteers with potential immune-mediated diseases
Endpoint domain: Adverse events/effects
Primary endpoint: CANTAB Paired Associates Learning (PAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Materno-fetal stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival (PFS) at One Year
Endpoint domain: Mortality/survival
Primary endpoint: Hepatic and skeletal muscle energy metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peripheral neuropathy detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-RT cardiovascular effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Plasma Levels of sCD14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Plasma Levels of sCD163
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in IL-6 Plasma Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in PpIX fluorescence at skin surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PpIX fluorescence biodistribution inside skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Concentrations of oral WCK 4873
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forward Flexion Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of TIL-ACT - successful Rapid Expansion Protocol (REP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of TIL-ACT - successful infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of TIL-ACT
Endpoint domain: Adverse events/effects
Primary endpoint: Psoriasis Area Severity Index 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measured CRT value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Fat via Fibroscan Controlled Attentuation Pattern score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in estimated HIV transmission
Endpoint domain: Mortality/survival
Primary endpoint: Illness absenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Silibinin Tissue Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal urinary iodine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroid measurements of fetal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in amplitudes of the N100 ERP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Latency of the N100 ERP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in amplitudes of the P300 ERP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Latency of the P300 ERP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in amplitudes of the N400 ERP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Number of Sexual Partners in Unprotected Anal Intercourse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Human anaerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in HIV-1 Levels in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathological complete response rate (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: additional identified dysplastic lesions on the cervix uteri
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cmax of plasma Budesonide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of plasma Budesonide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of plasma Formoterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of plasma Formoterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron concentration measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes